FrovatriptanThird Party Manufacturing in India

Frovatriptan is a selective serotonin receptor agonist with high affinity for 5-HT1B and 5-HT1D receptors, and weaker activity at 5-HT1F and 5-HT7 receptors. It works by binding to these receptors on cranial blood vessels, causing vasoconstriction of the dilated extracerebral and intracranial arteries that are responsible for the throbbing pain of migraine attacks. Simultaneously, frovatriptan inhibits the release of pro-inflammatory neuropeptides, including calcitonin gene-related peptide (CGRP) and substance P, from trigeminal nerve endings, thereby reducing neurogenic inflammation and pain signal transmission. Unlike most other triptans, frovatriptan also acts as a relatively potent agonist at 5-HT7 receptors, which may contribute to its therapeutic effects in migraine. The distinguishing feature of frovatriptan among the triptan class is its exceptionally long elimination half-life of approximately 26 hours, the longest in its class, which provides sustained migraine relief and a significantly lower rate of headache recurrence within 24 to 48 hours compared to shorter-acting triptans.

Therapeutic Uses

Frovatriptan is prescribed for the treatment of:

• Acute Migraine: Effective for the acute treatment of migraine attacks with or without aura in adults, providing rapid relief from headache pain, nausea, photophobia, and phonophobia.
• Menstrual Migraine Prophylaxis: Uniquely indicated for the short-term prevention of menstrual migraine when taken perimenstrually, with a 6-day dosing regimen significantly reducing the incidence of menstrual migraine attacks.
• Migraine Recurrence: Its long half-life results in one of the lowest headache recurrence rates among all triptans, making it particularly valuable for patients who experience frequent migraine recurrence with other medications.

Why Manufacturers Choose Frovatriptan

Frovatriptan occupies a specialized niche in the triptan market, distinguished by its exceptionally long half-life of 26 hours, the longest in its class. This unique pharmacokinetic profile translates to sustained relief and lower headache recurrence rates, providing a clear competitive advantage for PCD franchise and contract manufacturing offerings. The low dose requirement (2.5mg) makes frovatriptan a cost-effective molecule to manufacture from a raw material perspective. While the overall triptan market is specialized, frovatriptan's differentiated profile allows it to command premium pricing. Indian manufacturers with WHO-GMP certified facilities can serve both domestic prescription demand and export opportunities to regulated markets where frovatriptan is approved, including the US, Europe, and Canada.